Hormone replacement therapy after breast cancer: A review

Cancer Treatment Reviews

Volumn 22, Issue 5, 1996, Pages 335-343

  Eden, John A ^a   Wren, Barry G ^a  

^a ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CYCLINE; ESTROGEN; GESTAGEN; HORMONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; TAMOXIFEN;

BREAST CANCER; CANCER CELL; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CELL CYCLE G1 PHASE; CELL DIVISION; DIET; ESTROGEN METABOLISM; EXERCISE; FEMALE; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MENOPAUSAL SYNDROME; METASTASIS; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PREGNANCY; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

EID: 0030436623     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(96)90006-7     Document Type: Article

References (46)

1. Canney, P. A. & Hatton, M. Q. F. (1994) The prevalence of menopausal symptoms in patients treated for breast cancer. Clin. Oncol. 6: 297-299.
2. Lobo, R. A., McCormick, W., Singer, F. & Roy, S. (1994) Depot medroxyprogesterone acetate compared with conjugated oestrogens for the treatment of postmenopausal women. Obstet. Gynecol. 3: 1-5.
3. Schiff, I., Tulchinsky, D., Cramer, D. & Ryan, K. J. (1980) Oral medroxyprogesterone in the treatment of postmenopausal symptoms. J. Am. Med. Assoc. 244: 1443-1445.
4. Paterson, M. E. L. (1992) A randomized double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles. Br. J. Obstet. Gynaecol. 89: 464-472.
5. Eden, J. A. (1992) Oestrogen and the breast-myths about oestrogen and breast cancer. Med. J. Aust. 157: 175-177.
6. Eden, J. A. (1992) Oestrogen and the breast - the management of the menopausal woman with breast cancer. Med. J. Aust. 157: 247-250.
7. Law, M. R., Wald, N. J. & Meade, T. W. (1991) Strategies for prevention of osteoporosis and hip fracture. BMJ 303: 453-459.
8. Stampfer, M. J., Colditz, G. A., Willett W. C. et al. (1991) Postmenopausal oestrogen and cardiovascular disease. N. Engl. J. Med. 325: 756-762.
9. Vassilopoulou-Sellin, R. & Zolinski, C. (1992) Estrogen replacement therapy in women with breast cancer: a survey of patient's attitudes. Am. J. Med. Sci. 304: 145-149.
10. Love, R. R., Mazess, R. B., Barden, H. S. et al. (1992) Effects of tamoxifen on bone density in postmenopausal women with breast cancer. N. Engl. J. Med. 326: 852-856.
11. Fornandert Rutqvist L. E., Sjoberg, H. E., Blomquist, L., Mattoson, A. & Glas, U. (1990) Long term adjuvent tamoxifen in early breast cancer: effect on bone mineral in postmenopausal women. J. Clin. Oncol. 6: 1019-1024.
12. McDonald, C. C. & Stewart, H. J. (1991) Fatal myocardal infarction in the Scottish adjuvant tamoxifen trial. BMJ 303: 435-437.
13. Pardee, A. B. (1989) G1 events and regulation of cell proliferation. Science 246: 603-608.
14. Weinberg, R. A. (1995) The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
15. Sher, C. J. & Roberts, J. M. (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev.9: 1149-1163.
16. Lucas, J., Aagaard, L., Strauss, M. & Bartek, J. (1995) Oncogenic aberrations of p16 and cyclin D1 co-operate to de-regulate G1 control. Cancer Res. 55: 4818-4823.
17. Gail, M. H. & Benichou, J. (1991) Assessing the risk of breast cancer in individuals. Cancer Prev. 1: 1-15.
18. Henderson, B. E., Ross, R. & Berstein, L. (1988) Oestrogens as a cause of human cancer. Cancer Res. 48: 246-253.
19. Key, T. J. & Pike, M. C. (1985) The role of oestrogens and progestogens in the epidemiology of prevention of breast cancer. Eur. J. Cancer. 24: 29-43.
20. Bulbrook, R. D., Leake, E. & George, W. D. (1989) Oestrogens in the initiation and promotion of breast cancer. In: Beck, J. S. ed. Oestrogen and the Human Breast. Edinburgh: Royal Society of Edinburgh, pp. 67-76.
21. Blankenstein, M. A., Szymczak, J., Daroszewski, J. et al. (1992) Oestrogens and plasma fatty tissue from breast cancer patients and women undergoing surgery for non-oncological reasons. Gynecol. Endocrinol. 6: 13-17.
22. Bulun, S. E., Price, T. M., Aitken, J. et al. (1992) A link between breast cancer and local oestrogen biosynthesis suggested by quantification of breast and opposed tissue aromatase cytochrome P 450 transcripts using competitive polymerase chain reaction after reverse transcription. J. Clin. Endocrinol. Metab. 77: 162-168.
23. Fishman, J., Schneider, J., Herschopf, R. J. et al. (1984) Increased oestrogen 16α-hydroxylase activity in women with breast and endometrial cancer. J. Steroid Biochem. 20: 1077-1081.
24. Baldin, V., Lukas, J., Marcote, M. J., Pagano, M. & Draetta, G. (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7: 812-821.
25. Musgrove, E. A., Lee, C. S. L. & Sutherland, R. L. (1991) Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos, and c-myc genes. Mol. Cell. Biol. 11: 5032-5043.
26. Rose, C. & Mouridsen, H. T. (1989) Endocrine management of advanced breast cancer. Horm. Res. 32 (Suppl. 1): 189-197.
27. Wren, B. G. & Eden, J. A. (1996) Do progestogens reduce the risk of breast cancer? A review of the evidence. J Nth Am Menop Soc 3(1): 4-12.
28. Armstrong, B. K. (1988) Oestrogen therapy after the menopause - boon or bane? Med. J. Aust. 148: 213-214.
29. Dupont, W. D. & Page, D. L. (1991) Menopausal oestrogen replacement therapy and breast cancer. Arch. Intern. Med. 151: 67-72.
30. Steinberg, K. K., Thacker, S. B., Smith, S. J. et al. (1991) A meta-analysis of the effect of oestrogen replacement therapy on the risk of breast cancer. JAMA 265: 1985-1990.
31. Grady, D., Rubin, S. M., Petitti, D. B. et al. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 117: 1016-1037.
32. Sillero-Arenas, M., Delgado-Rodriguez, M., Rodriguez-Canteras, R., Bueno-Cavanillas, A. & Galvez-Vargas, R. (1992) Menopausal hormone replacement therapy and breast cancer; a metaanalysis. Obstet. Gynecol. 79: 286-294.
33. Colditz, G. A., Egan, K. M. & Stampfer, M. J. (1993) Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am. J. Obstet. Gynecol. 168: 1473-1480.
34. Ewertz, M. (1988) Influence of non-contraceptive exogenous and endogeneous sex hormones on breast cancer risk in Denmark. Int. J. Cancer 42: 832-883.
35. Colditz, G. A., Stampfer, M. J., Willett, W. C., Hennekens, C. H., Rosner, B. & Spieizer, F. E. (1990) Prospective study of oestrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 264: 2648-2653.
36. Hunt K., Vessey, M., McPherson, K. & Coleman, M. (1987) Long term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br. J. Obstet. Gynaecol. 94: 620-635.
37. Henderson, B. E., Maganini-Hill, A. & Ross, R. K. (1991) Decreased mortality in users of oestrogen replacement therapy. Arch. Intern. Med. 151: 75-78.
38. Bergkvist, L., Adami, H. Q., Perrson, I., Bergstrom, R. & Krusemo, U. B. (1989) Prognosis after breast cancer diagnosis in women exposed to oestrogen and oestrogen/progestogen replacement therapy. Am. J. Epidemiol. 130: 221-228.
39. Harding, C., Knox, F. W., Faragher, E. B., Baildam, A. & Bundred, N. J. (1996) Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. BMJ 312: 1646-1647.
40. Stoll, B. A. & Parbhoo, F. (188) Treatment of menopausal symptoms in breast cancer patients. Lancet i: 1278-1279.
41. Wile, A. G., Opfell, R. W. & Margileth, D. A. (1993) Hormone replacement in previously treated breast cancer patients. Am. J. Surg. 165: 372-375.
42. Di Saia, P. J. (1993) Hormone replacement therapy in patients with breast cancer. Cancer 71 (Suppl.): 1490-1500.
43. Powles, T. J., Hickish, T., Casey, S. & O'Brian, M. (1993) Hormone replacement therapy after breast cancer. Lancet 341: 60-61.
44. Bluming, A. Z., Wile, A. G., Schain, W. et al. Hormone replacement therapy in women with previous treated primary breast cancer. Proc. Annual Meet. Am. Soc. Clin. Oncol. 13: 137.
45. Eden, J. A., Bush, T., Nand, S. & Wren, B. G. (1995) A case-controlled study of combined continuous oestrogen-progestin replacement therapy among women with a personal history of breast cancer. J. Nth. Am. Menop. Soc. 2: 67-72.
46. Dhodapkar, M. V., Ingle, J. N. & Ahmann, D. L. (1995) Oestrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 75: 43-46.